HLS's Principal Activity is
the provision of pathology, imaging and day hospitals and also facilities & support services to general practitioners, radiologists and other healthcare professionals.
Share Price Activity
Last (Price)
Change
0.00
(0.00)
Bid / Ask
-
Volume
Volume (4w avg)
Turnover
Open
Day Range
-
VWAP
Prev Close
Last Trade
Performance
1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr)
+8.22%
vs ASX 200 (1yr)
+4.50%
Size
Market Cap
Excludes mandatory escrowed shares and foreign shares.
Healius Limited (HLS) is a healthcare company which provides facilities and support services to independent general practitioners, radiologists and a range of other healthcare professionals. Healius has three main businesses - Pathology, Imaging and Day Hospitals.
Incorporation Details
Incorporated Incorporated on 17 May 1994 in Victoria, Australia.
Professor Mattick is currently SHARP Professor of RNA Biology at UNSW Sydney. He was previously Chief Executive of Genomics England (2018-2019), and Director of the Garvan Institute of Medical Research in Sydney (2012-2018). He was appointed an Officer of the Order of Australia in 2001 for services to scientific research in the fields of molecular biology, genetics and biotechnology, particularly through the development and administration of research institutes and the Australian Genome Research Facility at the University of Queensland, where he was Foundation Director. He has over 300 research publications which have been cited over 80,000 times. He has been a member of the Australian Health Ethics Committee (AHEC) and the Research Committee of the National Health and Medical Research Council, and was involved in the development of the National Statement on the Ethical Conduct of Research involving Humans, the joint Australian Law Reform Commission (ALRC) / AHEC Commonwealth Inquiry into the Protection of Human Genetic Information, the Committee to Revise the Ethical Guidelines on Assisted Reproductive Technology, and the ALRC Reports on Gene Patenting and Genetic Privacy. He was also Chair of the Queensland Studies Authority. He has received numerous awards including the Advance Global Impact Award (2019), the University of Texas MD Anderson Cancer Center Bertner Award for Distinguished Contributions to Cancer Research (2014), the Human Genome Organisation Chen Medal for Distinguished Academic Achievement in Human Genetics and Genomic Research (2012), the International Union of Biochemistry and Molecular Biology Medal (2011), and the inaugural Gutenberg Chair at the University of Strasbourg (2007).
Ms Kathryn (Kate) Mary McKenzie
Non-Executive Director
Feb 2021
Ms Kathryn (Kate) Mary McKenzie
Non-Executive Director
Ms McKenzie was appointed as a Non-executive Director effective 25 February 2021. She was appointed as a member of the People & Governance Committee and as a member of the Risk Management Committee on the same date. She is a highly experienced Chief Executive Officer and Non-executive Director with experience in large change management. After starting her career in the public sector, she joined Telstra in 2004 as Group Managing Director Regulatory, Public Policy & Communications. In her 12 years at Telstra, she held a range of executive roles in strategy, marketing, products and wholesale. Prior to leaving Telstra, she was Chief Operating Officer, responsible for networks, IT, field services, property and NBN relations and delivery. In 2017 she was appointed Chief Executive Officer of Chorus, a New Zealand listed telecommunications company. She is passionate about innovation and technology, and co-founded muru-D, an incubator which has produced 44 graduating companies, with 41 still in operation; Gurrowa, a co-creation lab, and partnerships with universities, such as investment in Quantum Computing with the University of New South Wales
Ms Jennifer (Jenny) Mitchell Macdonald
Non-Executive Director
Nov 2020
Ms Jennifer (Jenny) Mitchell Macdonald
Non-Executive Director
Ms Macdonald was appointed as a Non-executive Director and Chair of the Audit Committee effective 3 November 2020. She has a strong background in financial and general management roles across a range of industry sectors including fast moving consumer goods, resources, travel and digital media. she commenced her career with KPMG, working in the London and Melbourne offices in a number of practice areas, including audit, she spent more than ten years with that firm. After gaining experience in the resources sector, she held executive roles in the travel and tourism industries and digital media at Flight Centre and REA Group. From 2014-2016 Jenny was the Chief Financial Officer and then Interim Chief Executive Officer of Helloworld, an ASX-listed multi-channel travel company.
Ms Alison Stephenson
Company Secretary
Aug 2019
Ms Sally Evans
Non-Executive Director
Aug 2018
Ms Sally Evans
Non-Executive Director
Ms Evans was appointed as a Non-executive Director in August 2018, also being appointed as a member of the Nomination and Remuneration Committee and the Risk Management Committee. On 19 August 2019, she was appointed as Chair of the newly renamed People & Governance Committee. Sally has over 30 years' experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the broader Asia Pacific region. She has served as a Non-executive Director of Gateway Lifestyle Operations Limited.
Dr Malcolm Parmenter
Chief Executive Officer,Managing Director
Sep 2017
Dr Malcolm Parmenter
Chief Executive Officer,Managing Director
Dr Parmenter joined Healius as Managing Director and Chief Executive Officer (CEO) in September 2017. He has a wealth of knowledge and practical experience in the operation of frontline care, with over nine years' tenure as CEO of Independent Practitioner Network Limited (IPN), both as a listed company and under the ownership of Sonic Healthcare Limited, and subsequently two years as CEO of Sonic Clinical Services. He has a strong understanding of healthcare delivery, both in Australia and abroad, and has spent more than 20 years as a General Practitioner.
Mr Gordon Richard Davis
Non-Executive Director
Aug 2015
Mr Gordon Richard Davis
Non-Executive Director
Mr Davis was appointed as a member of the Risk Management Committee and as Chair of the Risk Management Committee on 19 August 2019, at which time he ceased as Audit Committee Chair but remained a member of that committee. Prior to becoming a Non-executive Director, Gordon was Managing Director of AWB Limited between 2006 and 2010. He has also served in a senior capacity on various industry associations.
Mr Charles Tilley
Company Secretary
Feb 2015
Mr Robert Hubbard
Non-Executive Director,Non-Executive Chairman
Dec 2014
Mr Robert Hubbard
Non-Executive Director,Non-Executive Chairman
Mr Hubbard was a member of the Risk Management Committee up to that date. Rob Birmingham. He previously held partnership positions in the accounting, corporate finance, assurance and audit divisions of PricewaterhouseCoopers and acted as external auditor for some of Australia's largest ASX-listed companies.
Dr Paul Francis Jones
Non-Executive Director
Nov 2010
Dr Paul Francis Jones
Non-Executive Director
Dr Jones was appointed as a Non-executive Director in November 2010. During FY 2021, he was a member of the Audit Committee (from 25 February 2021), the People & Governance Committee and the Risk Management Committee (the latter until 25 February 2021). He has over 35 years' experience in a broad range of general medical practice, including 15 years' experience in Healius Group medical centres. He originally trained at the Repatriation and General Hospital, Concord NSW and subsequently at Calvary Public Hospital, Bruce ACT. He has been a Director and Federal Councillor of the Australian Medical Association (AMA), a past President of AMA ACT and a member of the Federal AMA Council of General Practice. He was formerly a general practitioner adviser to Calvary Public Hospital and held roles as GPVMO and Director, Medical Education Program. He is a former Chair of ACT GP Workforce Working Group and was a member of the ACT Health Minister's GP Task Force in 2009
Data supplied by Morningstar and accurate on Aug 31, 2021.
It's not possible to publish a real-time Top 20 Shareholder list.
Companies are not obliged to report this data (with the exception of Substantial
Shareholders above 5%). If a company chooses to publish the data,
it's usually once a year in their Annual Report.
All data is manually compiled so there might be a delay between the Annual Report
being published and the data appearing on Market Index (<7 days for ASX 300
and up to 30 days for micro-caps).
A substantial shareholder is a person or entity that owns 5% or more of
the voting shares in a company. Shares can be held through multiple
entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market.
When all “Last Notice” dates are identical, it suggests that no (or minimal)
change
has occurred since the most recent Annual Report.
Name
Last Notice
Total Shares
Shares Held (%)
Dimensional Entities
31/08/2021
30,485,918
6.04
Vinva Investment Management
28/02/2022
30,622,659
5.29
Australian Retirement Trust Pty Ltd
12/05/2022
30,839,249
5.33
Shareholders Buying
12 month transaction history compiled from ASX announcements.
Date
Name
Bought
Previous %
New %
12-05-22
Australian Retirement Trust Pty Ltd
30,839,249
--
5.33
28-02-22
Vinva Investment Management
30,622,659
--
5.29
22-07-21
Vinva Investment Management
31,595,448
--
5.07
Shareholders Selling
12 month transaction history compiled from ASX announcements.